CDK4 and interstitial lung disease: This considerable variability in ILD onset aligns with previous reports, which have demonstrated that ILD associated with CDK4/6 inhibitors can manifest at any stage of treatment, from as early as a few weeks to more than a year after therapy initiation [28,36].